Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by QContinuum1on Apr 23, 2024 1:18pm
113 Views
Post# 36003594

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CEO said, "we are undervalued". Okay, so how what is an

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CEO said, "we are undervalued". Okay, so how what is an
No reason to sell LABS yet, too many irons in the fire and potential for uptick.

That said, these irons need to materialize into concrete results this FY as there aren't any more excuses for kicking the can down the road.  If by end of calendar year, results and SP aren't materially higher, then we've been lied to and/or the LABS leadership team is lazy and/or they backed the wrong partners. 

Cash reserves are adequate, partner agreements are in place, product set is optimized, regulators have been appeased, jurisdictions have (and continue) to open.  If you can't grow a business as a prime mover with that type of tail wind, then I'm not sure what the heck one needs.  Stitch in apparent shortages of some products from other vendors and you may well have a perfect storm here. 

We certainly need to transition however from a reactionary onesy-twosy goods vendor to a sustainable contract based special product provider.  If our partners won't accept/agree to that, then they aren't partners and we need to find new ones.


<< Previous
Bullboard Posts
Next >>